Rodman & Renshaw analyst Ram Selvaraju weighed in today with a few insights on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), ahead of the the upcoming Phase 3 data from Synergy’s two pivotal trials of plecanatide in constipation-predominant irritable bowel syndrome (IBS-C). The analyst rates SGYP a Buy with price target of $15, which represents a potential upside of 258% from where the stock is currently trading.
Selvaraju wrote, “In our view, the fact that plecanatide has been shown to act in a pHdependent manner, forming a stable active conformer at pH 5, may explain why the drug—while able to restore normal gastrointestinal (GI) tract motility—would be less likely to cause excessive fluid secretion into the lower GI tract and thus induce diarrhea.”
“Given this mechanistic background, we believe that the Phase 3 IBS-C trials could demonstrate comparable efficacy of plecanatide to its sole marketed comparator, linaclotide, while further serving to underscore plecanatide’s superiority from a safety perspective. In anticipation of positive Phase 3 data from the IBS-C trials of plecanatide in the coming weeks, we reiterate our Buy,” the analyst continued.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ram Selvaraju has a yearly average return of -0.3% and a 41% success rate. Selvaraju has a 1.3% average return when recommending SGYP, and is ranked #2798 out of 4035 analysts.
All the 4 analysts polled by TipRanks rate Synergy Pharmaceuticals stock a Buy. With a return potential of 171.5%, the stock’s consensus target price stands at $11.38.